Biodyne KRX:314930KOSDAQ
바이오다인 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Biodyne reported revenue of ₩587m, down 67.2% year on year, and an operating loss of ₩681m. Biodyne (바이오다인) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Swung to loss Screener
Biodyne quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩587m | -67.2% | −₩681m margin −115.9% | −₩323m |
| Q1 2026 | ₩867m | -5.4% | −₩403m margin −46.5% | ₩155m |
| Q3 2025 | ₩859m | -43.4% | −₩383m margin −44.6% | ₩13m |
| Q2 2025 | ₩1.8bn | +45.4% | ₩299m margin 16.7% | −₩104m |
| Q1 2025 | ₩917m | -17.1% | −₩808m margin −88.2% | −₩435m |
| Q4 2024 derived | ₩1.4bn | +98.3% | −₩571m margin −40.4% | ₩447m |
| Q3 2024 | ₩1.5bn | +32.7% | −₩425m margin −28.0% | −₩384m |
| Q2 2024 | ₩1.2bn | – | −₩278m margin −22.6% | ₩150m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Biodyne top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Biodyne news Korean headlines
No articles yet.